In on-treatment specimens, CD39 expression remained increased on T-Ag–specific cells compared with VP1- and CEF-specific and bulk CD8+ T cells, both in the responding and nonresponding patients (Figure 4B), demonstrating CD39 as a signature of T-Ag recognition in MCC patients. This evidence concerns the gene CD8A and Merkel cell skin cancer.